FDA panel endorses first-of-a-kind cancer blood test from Grail
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"FDA panel endorses first-of-a-kind cancer blood test from Grail" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The New York Times and WSJ. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 54d ago.
Quick answers
Why is "FDA panel endorses first-of-a-kind cancer blood test from Grail" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- FDA panel endorses first-of-a-kind cancer blood test KCCI · 53d ago
- US FDA advisers endorse Grail cancer test's benefits in key vote Reuters · 54d ago
- FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test prnewswire.com · 54d ago
- FDA advisory panel endorses controversial cancer blood test The Seattle Times · 54d ago
- Cancer-screen blood test wins tepid support from US drug advisory panel ft.com · 54d ago
- Blood test for multiple cancers clears crucial hurdle on track to FDA approval Scientific American · 54d ago
- F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test The New York Times · 54d ago
- Grail’s Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval WSJ · 54d ago
Topics
Related trends
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.
Christina Applegate fears that ‘poisoning’ may be behind her misdiagnosis of MS
Christina Applegate reveals she is investigating whether breast implant illness caused her multiple sclerosis misdiagnosis, calling it potential 'poisoning.'